Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.
Galectins, soluble intracellular and extracellular beta-galactoside-binding proteins, are known to be involved in the progression and metastasis of various cancers, including prostate adenocarcinoma, but the detailed mechanism of their biological roles remains elusive. In the prostate cancer cell lines PC-3 and DU-145, galectin 3 (gal3) is present at normal levels, whereas in LNCaP, its expression is silenced. In LNCaP, the gal3 promoter was heavily methylated, whereas PC-3 or DU-145 cells showed negligible or no methylation in the gal3 promoter indicating a negative correlation between gal3 promoter methylation and its expression. On immunohistochemical analysis of normal and tumor prostate tissues, gal3 was found expressed both in nucleus and cytoplasm of benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and stage I. The expression of the gal3 was found drastically downregulated in advanced stages and, interestingly, mostly in the cytoplasm. On methylation analysis, the gal3 promoter in stage II prostate adenocarcinoma (PCa) was found heavily methylated, whereas in stages III and IV, it was only lightly methylated. However, in stage I PCa, both heavy and light methylations were observed in the gal3 promoter. In normal and benign prostatic hyperplasia tissues, the gal3 promoter was almost unmethylated. The differential cytosine methylation in the gal3 promoter in stages I to IV PCa enabled us to develop and validate a methylation-specific polymerase chain reaction-based sensitive assay specific for stages I and II PCa. These stages are considered the critical stages for successful intervention, thus underscoring the significance of this diagnostic assay.
Ahmed
Hafiz
H
University of Maryland Biotechnology Institute, 701 E Pratt St, Baltimore, MD 21202, USA.
Cappello
Francesco
F
Rodolico
Vito
V
Vasta
Gerardo R
GR
Cell Mol Life Sci. 2002 Feb;59(2):241-57
11915942
Expert Opin Ther Targets. 2007 Jan;11(1):81-90
17150036
Int J Cancer. 2000 Jul 20;89(4):361-7
10956411
J Natl Cancer Inst. 1998 Jul 1;90(13):1000-8
9665149
Am J Pathol. 1995 Sep;147(3):815-22
7677193
Am J Clin Pathol. 1999 May;111(5):623-31
10230352
Histol Histopathol. 2001 Jul;16(3):861-8
11510978
Gene Regul Syst Bio. 2007 Dec 11;1:313-25
19936097
Cancer Res. 2001 Jun 15;61(12):4820-6
11406558
Curr Opin Genet Dev. 1995 Jun;5(3):309-14
7549424
Clin Cancer Res. 2001 Sep;7(9):2727-30
11555585
Cancer Metastasis Rev. 2007 Dec;26(3-4):605-10
17726578
J Urol. 1994 Jun;151(6):1571-4
7514690
Nat Rev Genet. 2002 Jun;3(6):415-28
12042769
Int J Cancer. 1999 May 17;81(4):519-26
10225438
Cancer Metastasis Rev. 2007 Dec;26(3-4):567-78
17786537
Cancer. 1999 Dec 1;86(11):2353-63
10590378
J Mol Diagn. 2004 May;6(2):101-7
15096565
Clin Chem. 2008 May;54(5):874-82
18339699
Oncogene. 2004 Sep 30;23(45):7527-36
15326483
Oncogene. 2002 Aug 12;21(35):5400-13
12154403
Anticancer Agents Med Chem. 2008 Jan;8(1):22-36
18220503
Glycobiology. 2004 Mar;14(3):219-32
14693912
Curr Cancer Drug Targets. 2006 Sep;6(6):533-51
17017872
Cancer Treat Rev. 2002 Oct;28(5):255-71
12435372
Nat Rev Cancer. 2004 Feb;4(2):143-53
14732866
Cell Mol Life Sci. 2007 Jul;64(13):1679-700
17497244
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31
1542678
Glycoconj J. 2004;19(7-9):537-42
14758077
Front Biosci. 2007 May 01;12:3377-97
17485307
Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58
17635792
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7252-7
8692978
Clin Cancer Res. 2004 Dec 15;10(24):8472-8
15623627
Arch Biochem Biophys. 1998 Jan 1;349(1):7-20
9439577
Clin Chem. 2000 Aug;46(8 Pt 1):1078-84
10926886
Urology. 2007 Apr;69(4):714-20
17445657
Clin Chim Acta. 2001 Nov;313(1-2):143-6
11694252
Cancer Res. 2004 Jul 1;64(13):4442-52
15231653
J Clin Oncol. 2005 Sep 20;23(27):6569-75
16170165
Prostate. 2000 Jul 1;44(2):118-23
10881021
Cell. 2000 Jan 7;100(1):57-70
10647931
Expert Rev Mol Diagn. 2004 Jul;4(4):513-26
15225099
Cancer Res. 1999 Dec 15;59(24):6239-45
10626818
Clin Cancer Res. 2004 Aug 15;10(16):5518-22
15328191
Int J Cancer. 1994 Feb 15;56(4):474-80
8112883
Cancer Res. 2000 Nov 1;60(21):5941-5
11085508
Biochem Biophys Res Commun. 2007 Jun 22;358(1):241-6
17481580
Urol Res. 1999 Oct;27(5):362-7
10550525